The FDA has approved Zep Bound, a medication previously approved for weight loss, for the treatment of obstructive sleep apnea. This is significant as it is the first medication approved for this condition, which affects millions and is linked to serious health risks like diabetes, heart disease, and dementia. In clinical studies, up to 40% of patients experienced full resolution of their symptoms, effectively curing their sleep apnea. This approval could impact insurance coverage and Medicare, as the cost of such treatments is a major consideration. While the medication costs over $1,000 a month, the CDC reports that obesity-related health conditions cost over $170 billion annually, suggesting a potential economic benefit to broader coverage.